ExamFinch.com My Study

Study guide

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management

Practice this exam

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management

Key Takeaways Explain This Topic AI

The Monro-Kellie doctrine dictates that the rigid adult cranium has a fixed volume comprising brain parenchyma (~80%), blood (~10%), and cerebrospinal fluid (~10%); exhaustion of spatial compensatory displacement shifts the compliance curve to a steep elastance breakpoint where trivial volume additions cause catastrophic intracranial pressure spikes.

Cerebral Perfusion Pressure ( C P P = M A P − I C P CPP = MAP - ICP CPP = M A P − I CP ) must be maintained between 60 and 70 mmHg; targets below 60 mmHg induce cerebral ischemia, whereas aggressively forcing CPP above 70 mmHg with excessive fluids and vasopressors increases acute respiratory distress syndrome (ARDS) without improving neurological outcomes.

Normal ICP waveform displays a descending staircase configuration ( P 1 > P 2 > P 3 P_1 > P_2 > P_3 P 1 ​ > P 2 ​ > P 3 ​ ); elevation of the tidal wave ( P 2 > P 1 P_2 > P_1 P 2 ​ > P 1 ​ ) denotes exhausted intracranial compliance, while Lundberg A (plateau) waves signify severe sustained intracranial hypertension (50-100 mmHg for 5-20 minutes) heralding impending brain herniation.

The tiered ICP escalation protocol initiates baseline Tier 0 neuro-resuscitation (head of bed 30°, head midline, normothermia, analgesia/sedation, normocapnia PaCO2 35-40 mmHg), advances to Tier 1 (CSF drainage via EVD and osmotherapy with 3% hypertonic saline or mannitol targeting osmolar gap < 20 mOsm/kg), and reserves Tier 2 (neuromuscular blockade, rescue hyperventilation PaCO2 30-35 mmHg) for refractory surges.

Tier 3 refractory measures include pentobarbital coma titrated to electrographic burst suppression on continuous EEG, moderate hypothermia, and secondary decompressive craniectomy; the RESCUEicp trial demonstrated that decompressive craniectomy significantly reduces 6-month mortality in refractory ICP (26.9% vs 48.9%) at the expense of higher rates of vegetative survival and severe disability.

Last updated: October 2026

Monro-Kellie Doctrine, Volume-Pressure Dynamics & Intracranial Compliance

The intracranial vault in adults is an inflexible, non-distensible osseous cavity with an internal volume of approximately 1400 − 1700 mL 1400-1700\text{ mL} 1400 − 1700 mL . The Monro-Kellie doctrine states that this fixed intracranial volume is occupied by three non-compressible compartments:

V intracranial = V brain ( ≈ 80 % , 1200 − 1400 mL ) + V blood ( ≈ 10 % , 150 mL ) + V CSF ( ≈ 10 % , 150 mL ) V_{\text{intracranial}} = V_{\text{brain}} (\approx 80\%,\ 1200-1400\text{ mL}) + V_{\text{blood}} (\approx 10\%,\ 150\text{ mL}) + V_{\text{CSF}} (\approx 10\%,\ 150\text{ mL}) V intracranial ​ = V brain ​ ( ≈ 80% , 1200 − 1400 mL ) + V blood ​ ( ≈ 10% , 150 mL ) + V CSF ​ ( ≈ 10% , 150 mL )

Because the total skull volume is constant, the expansion of an existing compartment (e.g., cerebral edema, hyperemia, or hydrocephalus) or the emergence of an abnormal space-occupying lesion (e.g., epidural or subdural hematoma, intracerebral hemorrhage, tumor, abscess) must be compensated for by an equal volumetric reduction of the remaining compartments. Otherwise, intracranial pressure (ICP) must rise.

Spatial Compensation and the Volume-Pressure Curve

In the initial stages of expanding mass lesions, ICP remains within normal limits ( 5 − 15 mmHg 5-15\text{ mmHg} 5 − 15 mmHg ) through two primary compensatory displacement mechanisms:

Cerebrospinal Fluid (CSF) Translocation : CSF is rapidly displaced from the cerebral subarachnoid space and ventricular system downward into the distensible spinal subarachnoid thecal sac. Concurrently, CSF absorption through arachnoid granulations into the superior sagittal sinus accelerates.

Venous Blood Extrusion : Low-pressure cerebral venous blood is squeezed out of the cerebral veins and dural venous sinuses through the internal jugular veins into the systemic circulation. Intracranial Pressure (mmHg)

  • ^
  • 100|
  • | / (Terminal Decompensation)
  • 80| /
  • | / Elastance Breakpoint
  • 60| /
  • | /
  • 40| / <-- ICP > 22 mmHg (BTF Threshold)
  • | _________/
  • 20| ___________/
  • |________/ (Compensated Phase)
  • 0+----------------------------------------------------> Mass Volume (mL)

Once these spatial buffering reserves are exhausted—typically after 100 − 150 mL 100-150\text{ mL} 100 − 150 mL of compensatory displacement—the intracranial volume-pressure curve reaches its critical elastance breakpoint ( E = Δ P / Δ V E = \Delta P / \Delta V E = Δ P /Δ V ). At this steep inflection point, intracranial compliance ( C = Δ V / Δ P C = \Delta V / \Delta P C = Δ V /Δ P ) approaches zero. Consequently, tiny additions of volume ( 1 − 2 mL 1-2\text{ mL} 1 − 2 mL of hematoma growth or tissue edema) produce exponential, catastrophic spikes in ICP, resulting in microvascular collapse, acute cerebral ischemia, and fatal brainstem herniation.

Normal resting ICP in healthy supine adults ranges between 5 and 15 mmHg 5\text{ and }15\text{ mmHg} 5 and 15 mmHg . Pathological intracranial hypertension is defined as sustained ICP > 20 mmHg > 20\text{ mmHg} > 20 mmHg . The Brain Trauma Foundation (BTF 4th Edition) establishes an evidence-based clinical treatment threshold of ICP > 22 mmHg \text{ICP} > 22\text{ mmHg} ICP > 22 mmHg , as sustained pressures above this level correlate independently with increased mortality and poor functional recovery.

Cerebral Blood Flow, Autoregulation & Cerebral Perfusion Pressure (CPP)

Normal cerebral blood flow ( C B F CBF CBF ) is tightly regulated at approximately 50 mL/100 g brain tissue/min 50\text{ mL/100 g brain tissue/min} 50 mL/100 g brain tissue/min , consuming roughly 20 % 20\% 20% of resting total-body oxygen despite the brain accounting for only 2 % 2\% 2% of total body mass. The cerebral metabolic rate of oxygen consumption ( C M R O 2 CMRO_2 CMR O 2 ​ ) averages 3.0 − 3.5 mL O 2 /100 g/min 3.0-3.5\text{ mL } O_2\text{/100 g/min} 3.0 − 3.5 mL O 2 ​ /100 g/min :

C B F < 20 − 25 mL/100 g/min CBF < 20-25\text{ mL/100 g/min} CBF < 20 − 25 mL/100 g/min : Electrographic silence on EEG, loss of synaptic activity, and progressive clinical neurological deficits.

C B F < 10 − 12 mL/100 g/min CBF < 10-12\text{ mL/100 g/min} CBF < 10 − 12 mL/100 g/min : Failure of ATP-dependent N a + / K + Na^+/K^+ N a + / K + ATPase pumps, cytotoxic calcium influx, irreversible cell membrane depolarization, and neuronal necrosis (cerebral infarction).

Cerebral Perfusion Pressure Calculation and Autoregulatory Limits

Cerebral Perfusion Pressure (CPP) represents the net pressure driving blood across the cerebral capillary beds. It is calculated as the difference between systemic Mean Arterial Pressure ( M A P MAP M A P ) and Intracranial Pressure ( I C P ICP I CP ):

C P P = M A P − I C P CPP = MAP - ICP CPP = M A P − I CP

Note

If Central Venous Pressure ( C V P CVP C V P ) exceeds ICP (such as in severe right ventricular failure, mechanical ventilation with high PEEP, or superior vena cava syndrome), CVP replaces ICP as the effective backpressure: C P P = M A P − C V P CPP = MAP - CVP CPP = M A P − C V P .

In the uninjured brain, cerebral autoregulation dynamically adjusts cerebral arteriolar caliber (myogenic response) to preserve a constant C B F CBF CBF across CPP ranges between 50 and 150 mmHg 50\text{ and }150\text{ mmHg} 50 and 150 mmHg (or MAP 60 − 160 mmHg 60-160\text{ mmHg} 60 − 160 mmHg ):

When CPP drops, cerebral precapillary resistance arterioles dilate to maintain volumetric flow.

When CPP rises, arterioles constrict to protect fragile cerebral microvessels from hydrostatic rupture and hyperperfusion vasogenic edema.

In traumatic brain injury, acute ischemic stroke, subarachnoid hemorrhage, or severe intracranial hypertension, autoregulation is frequently disrupted or abolished. The cerebral circulation becomes "pressure-passive" —meaning C B F CBF CBF fluctuates linearly with systemic blood pressure. Under pressure-passive conditions, arterial hypotension precipitates immediate cerebral ischemia, while arterial hypertension exacerbates vasogenic cerebral edema and intracranial hypertension.

Guideline-Directed CPP Targets

The Brain Trauma Foundation guidelines recommend a target CPP of 60 to 70 mmHg 60\text{ to }70\text{ mmHg} 60 to 70 mmHg in patients with severe brain injury:

C P P < 60 mmHg CPP < 60\text{ mmHg} CPP < 60 mmHg : Substantially increases the risk of secondary cerebral ischemia and cellular death. Hypotension (defined as systolic blood pressure < 90 − 100 mmHg < 90-100\text{ mmHg} < 90 − 100 mmHg ) is an independent predictor of doubled mortality in severe TBI.

C P P > 70 mmHg CPP > 70\text{ mmHg} CPP > 70 mmHg : Aggressive pharmacologic elevation of CPP above 70 mmHg 70\text{ mmHg} 70 mmHg using excessive intravenous fluid boluses and high-dose vasopressor infusions does not improve neurological outcomes. Instead, randomized trials demonstrate that driving CPP > 70 mmHg > 70\text{ mmHg} > 70 mmHg produces a five-fold increase in Acute Respiratory Distress Syndrome (ARDS) due to hydrostatic capillary leak.

  • Invasive ICP Monitoring: Indications and Modalities
  • Clinical Indications for Invasive Monitoring

According to the Brain Trauma Foundation guidelines, invasive ICP monitoring is indicated in:

Patients with severe Traumatic Brain Injury (GCS 3 − 8 3-8 3 − 8 post-resuscitation) who demonstrate an abnormal admission non-contrast head CT (showing hematomas, contusions, cerebral swelling, herniation, or compressed/effaced basal cisterns).

Patients with severe TBI (GCS 3 − 8 3-8 3 − 8 ) with a normal head CT if two or more of the following adverse features are present on admission:

  • Age > 40 years > 40\text{ years} > 40 years
  • Unilateral or bilateral decerebrate or decorticate motor posturing
  • Systolic blood pressure < 90 mmHg < 90\text{ mmHg} < 90 mmHg

Selected non-traumatic neurocritical conditions: Poor-grade aneurysmal subarachnoid hemorrhage (Hunt and Hess 3-5), large intracerebral hemorrhage with intraventricular extension and hydrocephalus, massive ischemic stroke with malignant cerebral edema, and acute liver failure with Grade 3-4 hepatic encephalopathy undergoing evaluation for liver transplantation.

Monitoring Modalities: EVD vs. Intraparenchymal Microtransducer

Operational Feature External Ventricular Drain (EVD) Intraparenchymal Microtransducer

Sensing Technology Fluid-coupled strain-gauge transducer leveled to Foramen of Monro Fiberoptic or piezo-resistive strain gauge placed in white matter

Anatomical Target Ipsilateral frontal horn of lateral ventricle via Kocher's point Frontal white matter ( 1 − 2 cm 1-2\text{ cm} 1 − 2 cm deep via burr hole)

Therapeutic CSF Drainage Yes (Diagnostic AND therapeutic CSF diversion) No (Strictly diagnostic; cannot divert CSF)

Accuracy & Zero Drift Gold standard; can be recalibrated/zeroed at any time Low zero drift ( 1 − 2 mmHg/day 1-2\text{ mmHg/day} 1 − 2 mmHg/day ), but cannot be recalibrated in situ

Placement Feasibility Challenging if ventricles are effaced, slit, or midline-shifted Easily placed regardless of ventricular collapse or effacement

Infection Risk Ventriculitis/meningitis ( 5 − 10 % 5-10\% 5 − 10% ; escalates after 5-7 days) Low infection risk ( < 1 % < 1\% < 1% )

Hemorrhagic Risk Catheter tract hemorrhage ( 1 − 3 % 1-3\% 1 − 3% ) Minimal localized tract hemorrhage ( < 0.5 % < 0.5\% < 0.5% )

Tip

EVD Leveling and Drainage Modes :

The external pressure transducer must be strictly leveled to the Foramen of Monro , externally marked by the external acoustic meatus (tragus) . When drainage is continuous, the drip chamber is set at a designated hydrostatic height (e.g., 10 − 15 cmH 2 O 10-15\text{ cmH}_2\text{O} 10 − 15 cmH 2 ​ O above the tragus). To measure an accurate, non-artifactual ICP, the stopcock must be momentarily turned off to drainage so that the fluid column reflects intracranial parenchymal pressure rather than drainage chamber outflow resistance.

  • ICP Waveform Morphology, Compliance & Lundberg Waves
  • Pulse Waveform Morphology

The normal pulsatile ICP waveform is synchronized with each cardiac cycle and comprises three distinct, sequential peaks: Pressure (mmHg)

  • ^
  • | P1 (Percussion Wave)
  • | /\
  • | / \ P2 (Tidal Wave)
  • | / \ /\
  • | / \ / \ P3 (Dicrotic Wave)
  • | / \/ \ /\
  • | / \_/ \__
  • +-------------------------------------> Time
  • Normal Compliance: P1 > P2 > P3

P1 (Percussion Wave) : Originates from systemic arterial pulsations transmitted from the choroid plexus into the ventricular fluid column during ventricular systole. It exhibits a steep upstroke and constant amplitude.

P2 (Tidal Wave) : Represents the intracranial elastance and rebound of cerebral tissue against the rigid cranial vault. Under normal intracranial compliance, brain tissue readily absorbs the pulse, keeping P 2 P_2 P 2 ​ significantly shorter than P 1 P_1 P 1 ​ .

P3 (Dicrotic Wave) : Corresponds to aortic valve closure (dicrotic notch) and retrograde jugular venous pulsation.

Normal Intracranial Compliance : Manifests as a descending staircase pattern: P 1 > P 2 > P 3 P_1 > P_2 > P_3 P 1 ​ > P 2 ​ > P 3 ​ .

Compromised Intracranial Compliance (High Elastance) : As spatial buffering reserves are exhausted, the brain cannot absorb systolic expansion. The tidal wave elevates progressively until P 2 > P 1 P_2 > P_1 P 2 ​ > P 1 ​ , producing a rounded, pyramidal waveform. Elevation of P 2 P_2 P 2 ​ above P 1 P_1 P 1 ​ is a definitive sign of exhausted intracranial compliance, serving as an early warning of impending herniation even before mean numeric ICP crosses 22 mmHg 22\text{ mmHg} 22 mmHg .

Lundberg Pathological ICP Waves

In 1960, Nils Lundberg classified spontaneous ICP fluctuations into three clinical patterns:

Wave Type Amplitude & Duration Underlying Pathophysiology Clinical Significance

Lundberg A Waves (Plateau Waves) Sharp spikes of 50 − 100 mmHg 50-100\text{ mmHg} 50 − 100 mmHg lasting 5 − 20 minutes 5-20\text{ minutes} 5 − 20 minutes Severe cerebral vasoparalysis triggered by ischemia; cyclical vasodilation in poorly compliant brain Always pathological ; signifies imminent transtentorial herniation; requires emergent rescue therapy

Lundberg B Waves Rhythmic oscillations of 10 − 20 mmHg 10-20\text{ mmHg} 10 − 20 mmHg occurring every 0.5 − 2 cycles/min 0.5-2\text{ cycles/min} 0.5 − 2 cycles/min Fluctuations in cerebral vascular tone coupled to Cheyne-Stokes respiration or vasospasm Warns of unstable elastance, borderline autoregulation, and impending plateau wave decompensation

Lundberg C Waves Low-amplitude waves ( < 20 mmHg < 20\text{ mmHg} < 20 mmHg ) at 4 − 8 cycles/min 4-8\text{ cycles/min} 4 − 8 cycles/min Normal physiological oscillations linked to Traube-Hering-Mayer systemic blood pressure rhythms Benign physiological phenomenon ; seen in healthy autoregulating vasculature

Tiered Protocolized ICP Management

Management of intracranial hypertension follows a structured, step-wise tiered escalation framework established by the Neurocritical Care Society and Brain Trauma Foundation. Progression to higher tiers occurs only when lower-tier interventions fail to control ICP below 22 mmHg 22\text{ mmHg} 22 mmHg or CPP between 60 − 70 mmHg 60-70\text{ mmHg} 60 − 70 mmHg . [TIER 3: Refractory ICP Rescue]

  • Pentobarbital Coma | Hypothermia | Decompressive Craniectomy
  • ^
  • |
  • [TIER 2: Second-Line Interventions]
  • Neuromuscular Blockade | Temporary Hyperventilation (PaCO2 30-35) | MAP Optimization
  • ^
  • |
  • [TIER 1: First-Line Targeted Therapy]
  • EVD CSF Drainage | Osmotherapy (3% NaCl or Mannitol) | Repeat Imaging
  • ^
  • |
  • [TIER 0: Baseline Neuroprotection Bundle]
  • HOB 30° | Midline Head | Normothermia (36-37.5°C) | Light Sedation/Analgesia | PaCO2 35-40 | Euvolemia
  • Tier 0: Foundational Neuroprotection (Applied to All At-Risk Patients)

Positioning : Elevate head of bed to 30 ∘ 30^\circ 3 0 ∘ to enhance cerebral venous drainage via the internal jugular veins. Ensure head and neck remain strictly midline; avoid tight cervical collars, endotracheal tube ties, or neck rotation that compresses jugular venous return.

Normothermia : Maintain core body temperature strictly between 36.0 ∘ C 36.0^\circ\text{C} 36. 0 ∘ C and 37.5 ∘ C 37.5^\circ\text{C} 37. 5 ∘ C with scheduled antipyretics and advanced surface or intravascular targeted temperature management (TTM). Hyperthermia exponentially increases C M R O 2 CMRO_2 CMR O 2 ​ , cerebral blood volume, and ICP.

Analgesia and Sedation : Administer titratable short-acting agents (fentanyl, propofol) to control pain, coughing, agitation, and patient-ventilator dyssynchrony, which spike intrathoracic and intracranial pressures.

Ventilation : Maintain strict normocapnia with PaCO 2 35 − 40 mmHg \text{PaCO}_2\ 35-40\text{ mmHg} PaCO 2 ​ 35 − 40 mmHg and normoxia with PaO 2 ≥ 80 − 100 mmHg \text{PaO}_2 \ge 80-100\text{ mmHg} PaO 2 ​ ≥ 80 − 100 mmHg (or SpO 2 ≥ 94 % \text{SpO}_2 \ge 94\% SpO 2 ​ ≥ 94% ).

Fluid Balance : Maintain euvolemia using isotonic crystalloids (0.9% normal saline or Plasmalyte). Strictly avoid hypotonic solutions (e.g., 0.45% saline, lactated Ringer's, D5W), which lower serum osmolality and exacerbate cerebral edema.

Seizure Prophylaxis : Give phenytoin (the agent studied and supported by the Brain Trauma Foundation guideline) or levetiracetam (widely used, with similar efficacy in observational data) for 7 days after severe TBI to reduce early post-traumatic seizures; prophylaxis does not prevent late epilepsy.

Tier 1: First-Line Targeted Therapies (Sustained ICP > 22 mmHg)

Cerebrospinal Fluid Drainage via EVD :

Open the EVD to drain CSF at 10 − 15 cmH 2 O 10-15\text{ cmH}_2\text{O} 10 − 15 cmH 2 ​ O above the tragus.

Drain continuously or intermittently ( 5 − 10 mL 5-10\text{ mL} 5 − 10 mL aliquots) to decompress the ventricular space.

Osmotherapy: Hypertonic Saline vs. Mannitol :

Hypertonic Saline (3% NaCl) : Administer a bolus of about 250 mL 250\text{ mL} 250 mL IV over 15-30 minutes (about 3 – 5 mL/kg 3\text{--}5\text{ mL/kg} 3 – 5 mL/kg ), or 30 mL 30\text{ mL} 30 mL of 23.4 % 23.4\% 23.4% NaCl over 10-20 minutes via central venous catheter for acute herniation crises. Titrate continuous 3% infusion to maintain serum sodium between 145 and 155 mEq/L 145\text{ and }155\text{ mEq/L} 145 and 155 mEq/L and serum osmolality < 360 mOsm/kg < 360\text{ mOsm/kg} < 360 mOsm/kg .

Advantages : Draws parenchymal free water across an intact blood-brain barrier without inducing osmotic diuresis; expands intravascular volume, stabilizes MAP, and improves microvascular rheology.

Mannitol (20% solution) : Administer 0.5 − 1.0 g/kg 0.5-1.0\text{ g/kg} 0.5 − 1.0 g/kg IV bolus over 15-30 minutes through a dedicated in-line filter.

Mechanisms : Immediate plasma expansion decreases blood viscosity and induces reflex cerebral vasoconstriction within minutes, followed by delayed osmotic diuresis within 30-60 minutes.

Monitoring & Risks : Mannitol causes profound diuresis, hypovolemia, arterial hypotension, and prerenal azotemia. Serum osmolality and osmolar gap must be monitored closely:

Calculated Osm = 2 × [ Na + ] + [ Glucose ] 18 + [ BUN ] 2.8 \text{Calculated Osm} = 2 \times [\text{Na}^+] + \frac{[\text{Glucose}]}{18} + \frac{[\text{BUN}]}{2.8} Calculated Osm = 2 × [ Na + ] + 18 [ Glucose ] ​ + 2.8 [ BUN ] ​ Osmolar Gap = Measured Osm − Calculated Osm \text{Osmolar Gap} = \text{Measured Osm} - \text{Calculated Osm} Osmolar Gap = Measured Osm − Calculated Osm

Warning

Mannitol must be held if serum osmolality > 320 mOsm/kg > 320\text{ mOsm/kg} > 320 mOsm/kg or if the osmolar gap ≥ 20 mOsm/kg \ge 20\text{ mOsm/kg} ≥ 20 mOsm/kg . Continued administration beyond these thresholds leads to intrarenal accumulation of mannitol, severe renal vasoconstriction, and acute tubular necrosis (ATN).

Tier 2: Second-Line Interventions for Refractory Elevations

Neuromuscular Blockade : Administer a continuous infusion of a non-depolarizing neuromuscular blocking agent (e.g., cisatracurium) to abolish shivering, posturing, and ventilator dyssynchrony. Deep sedation (RASS -5) is mandatory prior to initiating chemical paralysis.

Controlled Temporary Hyperventilation : Titrate mechanical ventilation to achieve a target PaCO 2 \text{PaCO}_2 PaCO 2 ​ of 30 − 35 mmHg 30-35\text{ mmHg} 30 − 35 mmHg .

Mechanism : Hypocapnia alkalinizes the CSF and cerebral perivascular space, causing potent cerebral arteriolar vasoconstriction that shrinks cerebral blood volume ( C B V CBV CB V ) and rapidly reduces ICP.

Strict Precautions : Hyperventilation is strictly a temporary rescue bridge while definitive therapies are prepared. Never hyperventilate to PaCO 2 < 30 mmHg \text{PaCO}_2 < 30\text{ mmHg} PaCO 2 ​ < 30 mmHg or maintain hyperventilation beyond a few hours; severe vasoconstriction causes critical cerebral hypoperfusion, severe cellular ischemia, and secondary infarction.

MAP Augmentation : Titrate norepinephrine infusions to defend a CPP between 60 − 70 mmHg 60-70\text{ mmHg} 60 − 70 mmHg against escalating ICP.

Tier 3: Third-Line Interventions for Refractory Intracranial Hypertension

Barbiturate Coma : High-dose pentobarbital ( 10 mg/kg 10\text{ mg/kg} 10 mg/kg IV over 30 minutes, followed by 5 mg/kg/h × 3 hours 5\text{ mg/kg/h} \times 3\text{ hours} 5 mg/kg/h × 3 hours , then maintenance infusion of 1 − 2 mg/kg/h 1-2\text{ mg/kg/h} 1 − 2 mg/kg/h ) or thiopental.

Mechanism : Barbiturates profoundly depress cerebral metabolism ( C M R O 2 CMRO_2 CMR O 2 ​ ) and cerebral blood flow, contracting blood volume.

Titration : Continuous EEG (cEEG) monitoring is mandatory, titrating the infusion to burst suppression (target 1 burst per 10 − 20 seconds 10-20\text{ seconds} 10 − 20 seconds or 3 − 5 bursts/minute 3-5\text{ bursts/minute} 3 − 5 bursts/minute ).

Complications : Barbiturates induce profound myocardial depression, peripheral vasoplegia, refractory hypotension, paralytic ileus, and immunosuppression. Invasive arterial line monitoring and aggressive vasopressor infusions are required.

Moderate Therapeutic Hypothermia ( 32.0 − 34.0 ∘ C 32.0-34.0^\circ\text{C} 32.0 − 34. 0 ∘ C ) : Reduces C M R O 2 CMRO_2 CMR O 2 ​ by ≈ 7 % \approx 7\% ≈ 7% per 1 ∘ C 1^\circ\text{C} 1 ∘ C decrease. Highly prone to complications including coagulopathy, malignant arrhythmias, electrolyte shifts, and severe infections. In Eurotherm3235 (2015), hypothermia of 32 – 35 ∘ C 32\text{--}35^\circ\text{C} 32 – 3 5 ∘ C as stage-2 ICP therapy lowered ICP but worsened functional outcome, and POLAR (2018) found no benefit from early prophylactic hypothermia; it is now reserved for refractory cases.

Surgical Decompressive Craniectomy : Removal of a large osseous bone flap with duraplasty to provide physical decompression for swollen brain tissue.

Surgical Decompressive Craniectomy: The DECRA vs. RESCUEicp Evidence

The role of decompressive craniectomy in severe traumatic brain injury has been defined by two landmark multicenter randomized clinical trials:

1. The DECRA Trial (NEJM 2011)

Study Design : Evaluated early, secondary bifrontal decompressive craniectomy vs. medical therapy in patients with severe diffuse TBI who developed moderate, early refractory intracranial hypertension (ICP > 20 mmHg > 20\text{ mmHg} > 20 mmHg for > 15 minutes > 15\text{ minutes} > 15 minutes within a 1-hour window) despite Tier 1 medical management.

Outcomes : Bifrontal craniectomy rapidly lowered ICP and reduced mechanical ventilation duration and ICU length of stay. However, at 6 months, patients in the craniectomy group had significantly worse functional neurological outcomes on the Extended Glasgow Outcome Scale (GOSE) compared to medical therapy (unfavorable outcome 70 % 70\% 70% vs. 51 % 51\% 51% , odds ratio 2.21, p = 0.02 p=0.02 p = 0.02 ).

Conclusion : Early bifrontal decompressive craniectomy for mild-to-moderate refractory ICP is not recommended because it does not improve functional recovery and increases disability.

2. The RESCUEicp Trial (NEJM 2016)

Study Design : Evaluated secondary decompressive craniectomy (either unilateral frontotemporoparietal hemicraniectomy for focal lesions or bifrontal craniectomy for diffuse injury) vs. continued medical therapy (including barbiturate coma) in severe TBI patients with severe, sustained refractory intracranial hypertension (ICP > 25 mmHg > 25\text{ mmHg} > 25 mmHg for 1 to 12 hours 1\text{ to }12\text{ hours} 1 to 12 hours refractory to Tier 1 and Tier 2 therapies).

Outcomes : Secondary decompressive craniectomy resulted in a dramatic reduction in 6-month mortality ( 26.9 % 26.9\% 26.9% in the surgical group vs. 48.9 % 48.9\% 48.9% in the medical group, p < 0.001 p < 0.001 p < 0.001 ).

The Critical Trade-Off : The survival advantage was accompanied by a significant shift into surviving states with severe disability: at 6 months, vegetative survival was higher in the surgical group ( 8.5 % 8.5\% 8.5% vs. 2.1 % 2.1\% 2.1% ) as was lower severe disability ( 21.9 % 21.9\% 21.9% vs. 14.4 % 14.4\% 14.4% ). At 6 months, upper severe disability or better occurred in 42.8 % 42.8\% 42.8% vs. 34.6 % 34.6\% 34.6% (not significant); at 12 months this favorable outcome was 45.4 % 45.4\% 45.4% vs. 32.4 % 32.4\% 32.4% .

Conclusion : Decompressive craniectomy is a life-saving rescue procedure that averts death from herniation in refractory intracranial hypertension, but clinicians and surrogate decision-makers must recognize that survival often carries high rates of severe functional dependence.

Clinical Metric DECRA Trial (2011) RESCUEicp Trial (2016)

ICP Threshold for Enrollment Early mild-to-moderate: ICP > 20 mmHg \text{ICP} > 20\text{ mmHg} ICP > 20 mmHg for > 15 min >15\text{ min} > 15 min Severe sustained: ICP > 25 mmHg \text{ICP} > 25\text{ mmHg} ICP > 25 mmHg for 1 − 12 hours 1-12\text{ hours} 1 − 12 hours

Surgical Approach Exclusively bifrontal craniectomy Unilateral hemicraniectomy (unilateral swelling) or bifrontal craniectomy (diffuse swelling)

Control Group Care Standard medical therapy (no barbiturates) Continued medical therapy including Tier 3 barbiturates

6-Month Mortality No significant difference ( 19 % 19\% 19% surgical vs. 18 % 18\% 18% medical) Significant reduction ( 26.9 % 26.9\% 26.9% surgical vs. 48.9 % 48.9\% 48.9% medical, p < 0.001 p<0.001 p < 0.001 )

6-Month Functional Recovery Worse in surgical group (unfavorable GOSE 70 % 70\% 70% vs. 51 % 51\% 51% ) Reduced mortality, but increased vegetative state and severe disability